Drugs / 19-28z CAR T-cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04512716 | Feb 2021 → Jan 2027 expected | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, high grade B-cell lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01860937 | May 2013 → May 2027 expected | B-cell acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00466531 | Mar 2007 → Dec 2026 expected | leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19-28z CAR T-cells | “We undertook a multicenter clinical trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric/young adult patients (age, 1-22.5 years)...” PMID 31650176 ↗ Dec 20192“Conditioning chemotherapy and 19-28z CAR T-cells were acceptably tolerated across investigated dose levels in heavily pretreated patients with R/R CLL and indolent B-NHL.” PMID 30938714 ↗ Apr 2019 “19-28z CAR T-cells will be administered inpatient as a single infusion” NCT04512716 ↗ |
| Known as | 19-28z+ T cells | “Cohort 1 patients will receive conditioning chemotherapy followed by 1x10\^6 19-28z+ T cells/kg over 1 to 2 days.” NCT01860937 ↗ |
| Action | Deplete | “Using T cells from the patient that have been treated in the laboratory may help the body build an effective immune response to kill cancer cells.” NCT00466531 ↗ |
| Modality | Cell therapy | “autologous T cells genetically modified to express chimeric antigen receptor (CAR) targeting CD19 antigen (19-28z)” NCT00466531 ↗ |
| Target | CD19 | “CAR targeting CD19 antigen (19-28z)” NCT00466531 ↗ |